TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06016920: A Phase 1/2, Open-label Trial to Evaluate Safety, Immunogenicity, and Anti-tumor Activity of VB10.16 in Combination With Pembrolizumab in Patients With Unresectable Recurrent or Metastatic HPV16-positive Head and Neck Sq

Sponsor: Nykode Therapeutics ASA · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 110 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,443,050

Rescue Site Savings

+$5,576,340

Unlock Full NCT06016920 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06016920 Rescue Dossier →